<DOC>
	<DOC>NCT02462187</DOC>
	<brief_summary>This is a randomized, double-blind, vehicle-controlled, ascending dose study to assess safety, tolerability and efficacy of a topical nitric oxide releasing compound in subjects with external genital and perianal warts. Eligible subjects will be treated with a topical gel (active or vehicle) for up to 12 weeks.</brief_summary>
	<brief_title>Topical NVN1000 for the Treatment of External Genital and Perianal Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>At least 2 but not more than 20 genital/perianal warts with a maximum total wart surface area no more than 1% body surface area If a woman of childbearing potential, have a negative pregnancy test and use effective contraception If currently receiving wart treatment, be willing to stop all treatment for 28 days prior to randomization and during the study Immunocompromised patients including those with HIV, receiving radiation, or drugs that suppress the immune system Pregnant, planning to become pregnant, or nursing History of cancer (including cervical cancer) within 5 years, with exception of nonmelanoma skin cancer in nongenital skin Recent history of other genital skin infections Active HSV and frequent HSV recurrences unless receiving suppression therapy Have hemoglobin &lt; 10 G/dl or methemoglobin &gt; 3% Known allergy to any component of the gel including excipients Previously participated in any study with NVN1000 or SB204</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>genital warts</keyword>
	<keyword>perianal warts</keyword>
</DOC>